Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitafloxacin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 4/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitafloxacin Anhydrous SCHEMBL21416358 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL2784482 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL3198924 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL8509346 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL29821427 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL13483604 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL1652843 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL29368438 | 1.00 | ALDH1A1 (0.59) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL1060786 | 0.99 | POLB (0.58) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| Sitafloxacin Anhydrous SCHEMBL29391142 | 0.99 | POLB (0.58) | ALDH1A1POLBCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5095 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746896-A1 | TREATMENT OF STAPHYLOCOCCAL ABSCESSES | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-122036535-A | Antibacterial sitafloxacin preparation method of star intermediate | 惠州信立泰药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4658376-A1 | SKIN CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-1308160-A1 | HIGHLY ABSORBABLE SOLID PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | BAYER INNOVATION GMBH (DE) | 2003-03-06 | — | — | US | claimed |
| EP-1277471-A1 | STABLE LIQUID PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-22 | — | — | EP | claimed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | claimed |
| EP-1244434-A2 | USE OF CHEMOTHERAPEUTIC AGENTS | Schulz, Hans-Herrmann (DE) | 2002-10-02 | — | — | EP | claimed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | claimed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | claimed |
| EP-0643058-A1 | Crystals of an antimicrobial compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-03-15 | — | — | EP | claimed |